View
213
Download
0
Category
Tags:
Preview:
Citation preview
Atrial Fibrillation: Update 2007
David L. Scher, FACP, FACC, FHRSDirector, Cardiac Electrophysiology
Pinnacle Health System and Associated Cardiologists, PCHarrisburg, PA
Clinical Associate Professor of MedicinePennsylvania State College of Medicine
October 13, 2007
Atrial fibrillation accounts for 1/3 of all
patient discharges with arrhythmia as principal diagnosis.
2% VF
Data source: Baily D. J Am Coll Cardiol. 1992;19(3):41A.
34% Atrial
Fibrillation
18% Unspecified
6% PSVT
6% PVCs
4% Atrial Flutter
9% SSS
8% Conduction
Disease3% SCD
10% VT
Classification
• Paroxysmal: recurrent (>2 episodes) that terminate spontaneously within seven days.
• Persistent: AF with duration greater than seven days, or requiring CV (drugs or electrical). Also includes “longstanding persistent AF” (continuous AF lasting greater than one year).
• Permanent: AF in which decision not to restore SR by any means is made.
Atrial Fibrillation: Cardiac Causes• Hypertensive heart disease
• Ischemic heart disease
• Valvular heart disease
– Rheumatic: mitral stenosis
– Non-rheumatic: aortic stenosis, mitral regurgitation
• Pericarditis
• Sinus node dysfunction
• Cardiomyopathy
– Hypertrophic
– Idiopathic dilated (? cause vs. effect)
• Post-coronary bypass surgery
Atrial Fibrillation: Non-Cardiac Causes
• Pulmonary
– COPD
– Pneumonia
– Pulmonary embolism
• Metabolic
– Thyroid disease: hyperthyroidism
– Electrolyte disorder
– Acidemia, sepsis, other hyperadrenergic states
• Toxic: alcohol (‘holiday heart’ syndrome)
AF: Pathophysiology
Wavelets
AF: Pathophysiology
Wyse and Gersch, Circulation, 2004;109:3089-3095
AF: Pathophysiology
Wyse and Gersch, Circulation, 2004;109:3089-3095
Why Treat AF?
Wyse and Gersch, Circulation, 2004;109:3089-3095
2006 ACC/AHA/ESC Practice Guidelines: Changes Since 2001 Guidelines
• Incorporation of major clinical trials.• Reorganized with emphasis on clinical patient
management.• Incorporation of catheter-based ablation technologies.• Drug therapy: those approved in N. America and
Europe• Emerging importance of angiotensin inhibition.• Prophylactic therapies.
JACC 2006, 48:e149-246
Rate Control vs. Rhythm Control
StudiesAFFIRM (2002)
RACE (2002)PAF (2000)
STAF (2003)HOT CAFE’ (2004)
No study demonstrated a difference in quality of life!
Rate Control vs. Rhythm Control
• However, judgment should be exercised in applying this lack of difference of QOL to individual patients!
• Definition of rate control: less than 100 bpm over at least 18 hr monitoring period, or less than 100% of maximum age-adjusted predicted exercise heart rate.
• Regardless of treatment strategy, antithrombotic therapy is to be continued in indicated patients!
Clinical Management
Clinical Management
Clinical Management
Clinical Management: Which AA Drug?
Catheter and Surgical Ablation of AF
Atrial Fibrillation Ablation: HRS/EHRA/ECAS Expert Consensus
Statement
• Electrophysiologic basis and rationale
• Patient Selection
• Methods
• Complications
• Appropriate follow-up and long-term management
Ablation: Electrophysiologic Basis
Traditional Theory: Wavelets
Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins
Michel Haïssaguerre, M.D., Pierre Jaïs, M.D., Dipen C. Shah, M.D., Atsushi Takahashi, M.D., Mélèze Hocini, M.D.,
Gilles Quiniou, M.D., Stéphane Garrigue, M.D., Alain Le Mouroux, M.D., Philippe Le Métayer, M.D., and Jacques
Clémenty, M.D
Previous
Next
Volume 339:659-666
September 3, 1998
Number 10
Embryology of the Pulmonary Veins
Pulmonary Veins
Catheter Ablation of AF: Different Approaches
Patient Selection• Symptomatic AF refractory or intolerant to at least
one Class 1 or class 3 antiarrhythmic drug.
• Only absolute contraindication: LA thrombus (TEE before ablation in pts. with persistent AF).
• Other considerations:– Success less likely in pts. with marked LA dilatation.– Higher complication rate in very elderly.– Pts.’ desire to discontinue warfarin is not an
appropriate sole indication for ablation.
Complications
• Cardiac tamponade• Pulmonary vein stenosis• Atrio-esophageal fistula• Phrenic nerve injury• Thromboembolism
Complications
• Air embolism• Post-procedural arrhythmias• Vascular complications• Acute coronary occlusion• Periesophageal vagal injury
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• IV or LMW heparin bridging.
• Warfarin for at least 2 months in all patients.
• Decision re: warfarin after 2 months based on pt. risk factors NOT presence or absence of AF.
• Long-term warfarin for pts. With CHADS > 2.
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Repeat procedures: to be deferred for at least 3 months, if symptoms can be controlled with drugs.
• Definition of major complication: permanent injury, death, requiring intervention for treatment, or prolong or require hospitalization.
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Definition of success: freedom from AF/flutter/tachycardia is primary endpoint. Has varied: freedom for AF w/ and w/o sx, 90% reduction of AF burden, presence of AA drugs.
• Recurrence defined as AF/flutter/tachycardias documented lasting > 30 seconds (does not include early recurrence blanking period of 3 months).
• Early recurrence common and not failure: 35%, 40%, 45% at 15, 30, and 60 days respectively.
• Late recurrence (> 1 yr): 5-10%.
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Minimal monitoring: – office F/U 3 months post ablation and Q 6 mos. for 2
yrs.
– Event recorder monitoring for palpitations.
– 24-hour Holter monitoring at 3-6 mo. intervals for 1-2 yrs for clinical trials.
Literature Review: Non-randomized trials
• Single procedure success, %:– Paroxysmal AF: >60 (38-78)
– Persistent: <30 (22-45)
– Mixed: 16-84
• Multiple procedure success, %:– Paroxysmal: >70, (37-88)
– Persistent: >50 (37-88)
– Mixed: 31-80.
Literature Review: 5 Randomized trials
• 2005:70 pts randomized flecainide/sotalol or ablation:– recurrence= AF w/ or w/o sx.
– AA: 63%
– Abl: 13%
• 2006: (146 pts) Persistent AF CV vs. ablation:– Recurrence: freedom from AF/AFL w/o drugs.
– CV: 58%
– Abl: 74%
Literature Review: 5 Randomized trials
• 2006: (137 pts) Prospective: Role of abl as adjunctive Rx:– Recurrence: AA: 81%, ablation + AA: 45%
• 2006: (199 pts) Randomized, prospective: AA vs ablation:– Recurrence: AA: 78%, ablation: 14%
• 2006: (112 pts) AA vs ablation:– Recurrence: AA: 93%, ablation: 25%
– 63% of AA pts crossed over to ablation
Catheter Ablation of AF
J Cardiovasc Electrophysiol. 2006;17:1-6
Surgical Ablation of AF
• Concomitant to other open heart operations.
• Stand alone surgery for AF.
Surgical Ablation of AF: Concomitant to other open heart operations
• Rationale:
– AF is an independent predictor of late mortality.
– AF associated with higher periop mortality.
– Majority of pts with persistent AF before surgery remain unless treated at time of surgery.
Surgical Ablation of AF: Concomitant to Other Open Heart Operations
• Involves cryoablation, mocrowave, or RF ablation isolation of pulmonary veins and LA lesions (including line to MV-LA isthmus).
– Results: 76%success with LA isthmus lesions, 29% without (mean F/U 41 mos).
– LA appendage occlusion should be strongly considered.
– Results highly variable depending on energy source and completeness of ablation lines.
Stand-alone Surgical Ablation
Surgical Maze Procedure
Cox JL et al. Ann of Surgery 1996;224(3):267-75.
Cox MAZE III Procedure
Cox JL et al. Ann of Surgery 1996;224(3):267-75.
Bipolar clamp ablation
Gross Pathology
Atrial Appendage
Stand-alone Surgical Ablation of AF
Thromboembolic Risk: Pathophysiology
• Wyse and Gersch, Circulation, 2004;109:3089-3095
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
SUMMARY
• AF is the most common arrhythmia for which pts. are hospitalized.
• AF is associated with an icreased risk of morbidity and mortality.
• Rhythm control is not necessary in older pts. with minimal or absence of symptoms.
• AA drugs should be chosen based on side effect and proarrhythmic potential, not efficacy (except amio).
• Catheter and surgical ablation are effective in symptomatic pts. unresponsive to medical Rx.
• Antithrombotic therapy guidelines should be followed.
Recommended